Oaktree Acquisition III Stock Price, News & Analysis

Oaktree Acquisition Corp. III Life Sciences (OACC) is described as a blank check company and is classified in the Financial Services sector under shell companies. According to available regulatory filings, it is organized in the Cayman Islands and its securities are listed on The Nasdaq Stock Market LLC. The company’s structure includes units, Class A ordinary shares, and redeemable warrants, which are typical features of a blank check or special purpose acquisition vehicle.

The company’s units each consist of one Class A ordinary share with a par value of $0.0001 and one-fifth of one redeemable warrant. The Class A ordinary shares trade under the symbol OACC, the units under OACCU, and the redeemable warrants under OACCW on Nasdaq, as disclosed in its Form 8-K filings. Each whole warrant is exercisable for one Class A ordinary share at a specified exercise price.

Oaktree Acquisition Corp. III Life Sciences is incorporated in the Cayman Islands and has a connection to Oaktree Capital Management, L.P., as indicated by the appointment of a senior Oaktree finance executive as Chief Financial Officer. The company’s filings also reference Oaktree Acquisition Holdings III LS, LLC, in connection with potential non-controlling minority investments by independent directors. This underscores the company’s relationship with Oaktree-affiliated entities within its governance and capital structure.

The company’s principal executive offices are referenced in SEC filings as being located in Los Angeles, California (city and state only), while its jurisdiction of incorporation remains the Cayman Islands. This combination of a Cayman Islands incorporation and U.S.-based executive office location is common among blank check entities that seek listings on U.S. exchanges.

The governance structure of Oaktree Acquisition Corp. III Life Sciences, as reflected in its 8-K filings, includes a board of directors with independent directors who may serve on key committees such as the audit, nominating, and compensation committees. These committees are important for overseeing financial reporting, director nominations, and executive-related matters in line with Nasdaq listing standards and U.S. securities regulations.

Recent Form 8-K filings highlight changes in the company’s leadership. One filing reports the resignation of a Chief Financial Officer and the appointment of a new Chief Financial Officer, who also serves as the principal accounting and principal financial officer. Another filing reports the appointment of an independent director who is expected to serve on multiple board committees. In both cases, the filings state that the appointees are not receiving direct compensation from the company for these roles and that they are expected to enter into indemnity and letter agreements similar to those of other directors and officers.

The company’s filings indicate that independent directors may have the opportunity to make a non-controlling minority investment in Oaktree Acquisition Holdings III LS, LLC. This structure is described in the company’s Annual Report on Form 10-K, which is referenced in the 8-K filings as containing the forms of relevant indemnity and letter agreements. These documents help define the rights and protections of directors and officers in connection with their service to the company.

As a blank check entity, Oaktree Acquisition Corp. III Life Sciences is categorized among shell companies in the Financial Services sector. Its public disclosures focus on its capital structure (units, shares, and warrants), governance arrangements, and board and officer appointments, rather than on operating businesses or products. Investors and observers typically review the company’s SEC filings to understand its structure, governance, and any material events affecting its securities.

Business Structure and Securities

Oaktree Acquisition Corp. III Life Sciences has three main classes of listed securities described in its SEC filings:

• Units, each consisting of one Class A ordinary share and one-fifth of one redeemable warrant, trading under the symbol OACCU on Nasdaq.
• Class A ordinary shares, which are included as part of the units and trade separately under the symbol OACC on Nasdaq.
• Redeemable warrants, which are included as part of the units and trade under the symbol OACCW on Nasdaq, with each whole warrant exercisable for one Class A ordinary share at a stated exercise price.

This structure is designed to give investors exposure to the company’s Class A ordinary shares and potential additional equity through the exercise of warrants, as disclosed in its 8-K filings.

Governance and Board Composition

The company’s governance framework, as described in its SEC reports, includes a board of directors with independent members. One independent director is noted as serving as a Class II director and as a member of the audit, nominating, and compensation committees. The filings also state that this director meets the independence requirements under Nasdaq listing standards and Rule 10A-3 under the Exchange Act.

Board and officer appointments and departures are reported under Item 5.02 of Form 8-K, which covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. These disclosures provide transparency into the company’s leadership and oversight arrangements.

Relationship with Oaktree-Affiliated Entities

According to the company’s 8-K filings, its Chief Financial Officer is a Senior Vice President within Oaktree Capital Management, L.P.’s finance organization, overseeing accounting, operations, and reporting functions for Oaktree’s corporate accounting organization. The filings also reference Oaktree Acquisition Holdings III LS, LLC in connection with potential minority investments by independent directors. These disclosures indicate a close relationship between the company and Oaktree-affiliated entities in terms of management and governance.

Regulatory and Reporting Framework

Oaktree Acquisition Corp. III Life Sciences files reports with the U.S. Securities and Exchange Commission, including Form 10-K for annual reporting and Form 8-K for current reports on material events. Its filings reference compliance with Nasdaq listing standards and relevant Exchange Act rules related to independent directors and audit committee composition. The company’s status as a blank check or shell company is reflected in its industry classification and in the nature of its public disclosures.

FAQs about Oaktree Acquisition Corp. III Life Sciences (OACC)